Systematic review and meta-analysis of Endostar (rh-endostatin) combined with chemotherapy versus chemotherapy alone for treating advanced non-small cell lung cancer

World Journal of Surgical Oncology

Research

Yang Shuanying¹  Ming Zongjuan¹  Li Wei¹  Rong Biaoxue¹  Zhang Wei² 

[1] Department of Respiratory Medicine, The Second Affiliated Hospital of Xi’an Jiaotong University, 157 Xi-Wu Road, 710004, Xi’an, Shaanxi, China;Department of Thoracic Surgery, The Second Affiliated Hospital of Xi’an Jiaotong University, 157 Xi-Wu Road, 710004, Xi’an, Shaanxi, China;

关键词: Recombinant human endostatin;    Endostar;    YH-16;    Lung cancer;    First-line chemotherapy;    Meta-analysis;   

DOI  :  10.1186/1477-7819-10-170

 received in 2012-03-14, accepted in 2012-07-27,  发布年份 2012

来源: Springer

【 摘 要 】

BackgroundMany studies have investigated the efficacy of Endostar combined with platinum-based doublet chemotherapy (PBDC) versus PBDC alone for treating advanced non-small cell lung cancer (NSCLC). This study is a meta-analysis of available evidence.MethodsFifteen studies reporting Endostar combined with PBDC versus PBDC alone for treating advanced NSCLC were reviewed. Pooled odds ratios and hazard ratio with 95% confidence intervals were calculated using either the fixed effects model or random effects model.ResultsThe overall response rate (ORR) and disease control rate (DCR) of Endostar combined with PBDC for treating NSCLC were significantly higher than those of PBDC alone, with 14.7% and 13.5% improvement, respectively (P < 0.00001). In addition, the time to progression (TTP) and quality of life (QOL) were improved after the treatment of Endostar combined with PBDC (P < 0.00001). The main adverse effects found in this review were hematological reactions, hepatic toxicity, and nausea/vomiting. Endostar combined with PBDC had a similar incidence of adverse reactions compared with PBDC alone (P < 0.05).ConclusionsEndostar combined with PBDC was associated with higher RR, DCR, and TTP as well as superior QOL profiles compared with PBDC alone. Endostar combined with PBDC had a similar incidence of adverse reactions compared with PBDC alone.

【 授权许可】

Unknown   
© Biaoxue et al.; licensee BioMed Central Ltd. 2012. This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.